Diabetes remains the most common cause of neuropathy
in the United States and is a significant source of morbidity and mortality, accounting for substantial suffering and billions of dollars in health care expenditures each year.
Our insight into the pathophysiology of the diabetic neuropathies has increased considerably over the last decade, aided by advances in the basic science of diabetes itself. A wide variety of potential mechanisms for nerve injury in diabetes has been identified, including the polyol pathway of glucose metabolism, oxidative nerve injury, the deposition of advanced glycosylation end products within the nerve and the effects of vascular insufficiency, among others. Diabetic neuropathy
may take variety of clinical forms beyond the well-know distal symmetric neuropathy
, many of which are often misdiagnosed or overlooked entirely, sometimes with serious consequences for the patient. Proper therapy after diagnosis is also critical and may include not only primary management, but also treatment
of painful diabetic neuropathy
through an expanding repertoire of increasingly effective pharmacologic agents. Though primary treatment
trials have not yet provided effective therapies, ongoing and future trials offer continuing promise.
The diabetic neuropathies are exceedingly common, but often improperly diagnosed and incompletely treated. A proper understanding of the mechanisms underlying these diseases and the clinical recognition of their various forms is highly important as appropriate primary and symptomatic management can substantially reduce the morbidity and mortality associated with these disorders.